A citation-based method for searching scientific literature

Kim A Papp, Andrew Blauvelt, Michael Bukhalo, Melinda Gooderham, James G Krueger, Jean-Philippe Lacour, Alan Menter, Sandra Philipp, Howard Sofen, Stephen Tyring, Beate R Berner, Sudha Visvanathan, Chandrasena Pamulapati, Nathan Bennett, Mary Flack, Paul Scholl, Steven J Padula. N Engl J Med 2017
Times Cited: 285







List of co-cited articles
1061 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis.
Yaowei Zhu, Chuanpu Hu, Ming Lu, Sam Liao, Joseph C Marini, Jennifer Yohrling, Newman Yeilding, Hugh M Davis, Honghui Zhou. J Clin Pharmacol 2009
125
5

Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis.
Guomei Xu, Meng Xia, Chenjie Jiang, Ying Yu, Guomi Wang, Jiaojiao Yuan, Xingwu Duan. J Pharmacol Sci 2019
19
26

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.
U Chaudhari, P Romano, L D Mulcahy, L T Dooley, D G Baker, A B Gottlieb. Lancet 2001
727
5

A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.
Christi Parham, Madaline Chirica, Jacqueline Timans, Elena Vaisberg, Marilyn Travis, Jeanne Cheung, Stefan Pflanz, Rebecca Zhang, Komal P Singh, Felix Vega,[...]. J Immunol 2002
961
5


The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Jerry Bagel, Kristina Callis Duffin, Angela Moore, Laura K Ferris, Kimberly Siu, Jennifer Steadman, Farid Kianifard, Judit Nyirady, Mark Lebwohl. J Am Acad Dermatol 2017
54
9

Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
D Thaçi, K Unnebrink, M Sundaram, S Sood, Y Yamaguchi. J Eur Acad Dermatol Venereol 2015
47
10

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.
Phyllis I Spuls, Lidian L A Lecluse, Marie-Louise N F Poulsen, Jan D Bos, Robert S Stern, Tamar Nijsten. J Invest Dermatol 2010
152
5

Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation.
Yihua Cai, Xiaoyan Shen, Chuanlin Ding, Chunjian Qi, Kejia Li, Xia Li, Venkatakrishna R Jala, Huang-ge Zhang, Tian Wang, Jie Zheng,[...]. Immunity 2011
661
5

Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
Jerry Bagel, Charles Lynde, Stephen Tyring, Gregory Kricorian, Yifei Shi, Paul Klekotka. J Am Acad Dermatol 2012
74
6

Risk of myocardial infarction in patients with psoriasis.
Joel M Gelfand, Andrea L Neimann, Daniel B Shin, Xingmei Wang, David J Margolis, Andrea B Troxel. JAMA 2006
4

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, Bruce Randazzo, Michael Song, Shu Li, Yaung-Kaung Shen, Andrew Blauvelt. J Drugs Dermatol 2018
26
15

Definition of treatment goals for moderate to severe psoriasis: a European consensus.
U Mrowietz, K Kragballe, K Reich, P Spuls, C E M Griffiths, A Nast, J Franke, C Antoniou, P Arenberger, F Balieva,[...]. Arch Dermatol Res 2011
493
4


Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
Kim Papp, Herve Bachelez, Antonio Costanzo, Peter Foley, Melinda Gooderham, Primal Kaur, Joanna Narbutt, Sandra Philipp, Lynda Spelman, Jolanta Weglowska,[...]. J Am Acad Dermatol 2017
71
5

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
Ulrich Mrowietz, Craig L Leonardi, Giampiero Girolomoni, Darryl Toth, Akimichi Morita, Shyamal A Balki, Jacek C Szepietowski, Pascaline Regnault, Helen Thurston, Charis Papavassilis. J Am Acad Dermatol 2015
137
4


Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Mamitaro Ohtsuki, Yukari Okubo, Mayumi Komine, Shinichi Imafuku, Robert M Day, Peng Chen, Rosemary Petric, Allan Maroli, Osamu Nemoto. J Dermatol 2017
37
10

An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Richard B Warren, Ulrich Mrowietz, Ralph von Kiedrowski, Johannes Niesmann, Dagmar Wilsmann-Theis, Kamran Ghoreschi, Ina Zschocke, Thomas M Falk, Norbert Blödorn-Schlicht, Kristian Reich. Lancet 2017
57
7

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
K A Papp, M A Menter, M Raman, D Disch, D E Schlichting, C Gaich, W Macias, X Zhang, J M Janes. Br J Dermatol 2016
139
4

Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.
Kristian Reich, Kim A Papp, Robert T Matheson, John H Tu, Robert Bissonnette, Marc Bourcier, David Gratton, Rodion A Kunynetz, Yves Poulin, Les A Rosoph,[...]. Exp Dermatol 2015
118
4

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Séverine Vermeire, William J Sandborn, Silvio Danese, Xavier Hébuterne, Bruce A Salzberg, Maria Klopocka, Dino Tarabar, Tomas Vanasek, Miloš Greguš, Paul A Hellstern,[...]. Lancet 2017
107
4

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
515
4

Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways.
Rajan P Nair, Kristina Callis Duffin, Cynthia Helms, Jun Ding, Philip E Stuart, David Goldgar, Johann E Gudjonsson, Yun Li, Trilokraj Tejasvi, Bing-Jian Feng,[...]. Nat Genet 2009
980
4


Ulcerative colitis.
Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet, Jean-Frédéric Colombel. Lancet 2017
4

IL-23 promotes tumour incidence and growth.
John L Langowski, Xueqing Zhang, Lingling Wu, Jeanine D Mattson, Taiying Chen, Kathy Smith, Beth Basham, Terrill McClanahan, Robert A Kastelein, Martin Oft. Nature 2006
724
4

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
K Reich, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, A B Kimball. Br J Dermatol 2019
38
10


A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.
Philip J Mease, Josef S Smolen, Frank Behrens, Peter Nash, Soyi Liu Leage, Lingnan Li, Hasan Tahir, Melinda Gooderham, Eswar Krishnan, Hong Liu-Seifert,[...]. Ann Rheum Dis 2020
106
4

Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
Yukari Okubo, Mamitaro Ohtsuki, Akimichi Morita, Masako Yamaguchi, Tomohiro Shima, Yumiko Tani, Hidemi Nakagawa. J Dermatol 2019
13
30


Risankizumab: First Global Approval.
Kate McKeage, Sean Duggan. Drugs 2019
31
12

Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders.
M J Gooderham, K A Papp, C W Lynde. J Eur Acad Dermatol Venereol 2018
42
9

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Dominique Baeten, Joachim Sieper, Jürgen Braun, Xenofon Baraliakos, Maxime Dougados, Paul Emery, Atul Deodhar, Brian Porter, Ruvie Martin, Mats Andersson,[...]. N Engl J Med 2015
562
4

Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases.
George E Fragoulis, Stefan Siebert, Iain B McInnes. Annu Rev Med 2016
104
4

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.
Laurie E Harrington, Robin D Hatton, Paul R Mangan, Henrietta Turner, Theresa L Murphy, Kenneth M Murphy, Casey T Weaver. Nat Immunol 2005
4

IL-12 family cytokines: immunological playmakers.
Dario A A Vignali, Vijay K Kuchroo. Nat Immunol 2012
737
4

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
247
4

The immunogenetics of Psoriasis: A comprehensive review.
Jamie L Harden, James G Krueger, Anne M Bowcock. J Autoimmun 2015
295
4

Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.
Craig A Murphy, Claire L Langrish, Yi Chen, Wendy Blumenschein, Terrill McClanahan, Robert A Kastelein, Jonathon D Sedgwick, Daniel J Cua. J Exp Med 2003
4


Economic Burden of Psoriasis in the United States: A Systematic Review.
Elizabeth A Brezinski, Jaskaran S Dhillon, April W Armstrong. JAMA Dermatol 2015
133
4

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
88
4

Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.
Philip J Mease, Dafna D Gladman, Kim A Papp, Majed M Khraishi, Diamant Thaçi, Frank Behrens, Robert Northington, Joanne Fuiman, Eustratios Bananis, Robert Boggs,[...]. J Am Acad Dermatol 2013
267
4

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.
Alice Gottlieb, Alan Menter, Alan Mendelsohn, Yaung-Kaung Shen, Shu Li, Cynthia Guzzo, Scott Fretzin, Rod Kunynetz, Arthur Kavanaugh. Lancet 2009
430
4


Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
Richard B Warren, Melinda Gooderham, Russel Burge, Baojin Zhu, David Amato, Karen Huayu Liu, David Shrom, Jiaying Guo, Alan Brnabic, Andrew Blauvelt. J Am Acad Dermatol 2020
23
17

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis.
Wenjun Geng, Jianhua Zhao, Jixing Fu, Huamin Zhang, Shaohua Qiao. Exp Ther Med 2018
13
30



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.